Key result
Cancer patients admitted to the ICU face ~41% mortality, predicted by APACHE II and ECOG 4.
Why the study?
Advances in cancer treatment and an aging population have increased ICU admissions among patients with cancer, while mortality remains high and ICU resources are limited.
Cohort (n=287)
Blinded to outcomes (reviewers)
No
Odds Ratio: 1.15
Clinical and oncological information available at admission, such as APACHE II score and ECOG status, can predict ICU mortality and support evidence-based triage in patients with cancer.
APACHE II and ECOG may aid admission risk stratification in cancer ICU patients; leaves open prospective validation of prioritization guidelines.
Background/Objectives: Advances in cancer treatment and an aging population have increased ICU admissions among patients with cancer, while mortality remains high and ICU resources are limited. We aimed to identify mortality predictors available at admission and factors arising during the ICU stay and to evaluate retrospective concordance with ICU admission-prioritization guidelines. Methods: This retrospective single-center cohort included 287 patients with an active malignancy admitted to an oncology ICU in Lublin, Poland, from 1 January 2024 through 31 December 2025. Two independent reviewers, blinded to outcomes, retrospectively assigned ICU admission priorities according to Polish Society of Anaesthesiology and Intensive Therapy guidelines. Univariable and multivariable logistic regression analyses were used to identify factors associated with ICU mortality. Results: Overall ICU mortality was 41.1% (118/287). In the adjusted admission-time model, APACHE II score (odds ratio (OR), 1.15 per point), ECOG 4 (OR, 6.37), and postoperative admission (OR, 0.29) were associated with mortality (area under the receiver operating characteristic curve (AUC), 0.84). In the exploratory ICU-course model, mechanical ventilation >48 h or death within 48 h while mechanically ventilated (OR, 6.79) and vasopressor therapy >48 h or death within 48 h while receiving vasopressors (OR, 4.33) were associated with mortality. The proportion of priority-4 admissions decreased from 19.2% (24/125) in 2024 to 4.9% (8/162) in 2025 (p < 0.001). Priority-4 classification remained associated with ICU mortality even after adjustment for APACHE II score. Conclusions: Cancer, even at an advanced stage, should not be regarded as an absolute contraindication to intensive care. Clinical and oncological information available at admission may support evidence-based ICU triage. Structured prioritization may help identify patients with a very limited likelihood of benefiting from intensive care and support responsible allocation of critical care resources.
No takes yet. Share an insight, caveat, or question.
Kosz et al. (2026) conducted a cohort in Active malignancy requiring ICU admission (n=287). Clinical and oncological predictors (APACHE II, ECOG 4) vs. Lower scores or absence of risk factors was evaluated on ICU mortality (OR 1.15 per point (APACHE II), OR 6.37 (ECOG 4)). In patients with cancer admitted to the ICU, overall mortality was 41.1%, with APACHE II score (OR 1.15 per point) and ECOG 4 (OR 6.37) identified as significant predictors of ICU mortality.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: